Cargando…

The Emerging Role of m6A Modification in Endocrine Cancer

SIMPLE SUMMARY: Endocrine tumors often cause hormonal imbalances and sometimes hormone syndrome. Generally, the prognosis of patients with metastatic endocrine malignancies is poor due to recurrence and treatment failure. Aberrant expression of m6A may disrupt the development and occurrence of malig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Xiaoyu, Wang, Zhiyuan, Sun, Wei, Zhang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954123/
https://www.ncbi.nlm.nih.gov/pubmed/36831377
http://dx.doi.org/10.3390/cancers15041033
_version_ 1784894049051738112
author Ji, Xiaoyu
Wang, Zhiyuan
Sun, Wei
Zhang, Hao
author_facet Ji, Xiaoyu
Wang, Zhiyuan
Sun, Wei
Zhang, Hao
author_sort Ji, Xiaoyu
collection PubMed
description SIMPLE SUMMARY: Endocrine tumors often cause hormonal imbalances and sometimes hormone syndrome. Generally, the prognosis of patients with metastatic endocrine malignancies is poor due to recurrence and treatment failure. Aberrant expression of m6A may disrupt the development and occurrence of malignancies. We provide a theoretical foundation for the development of new diagnostic markers and therapeutic techniques based on m6A alteration and regulators in endocrine cancers. ABSTRACT: With the development of RNA modification research, N6-methyladenosine (m6A) is regarded as one of the most important internal epigenetic modifications of eukaryotic mRNA. It is also regulated by methylase, demethylase, and protein preferentially recognizing the m6A modification. This dynamic and reversible post-transcriptional RNA alteration has steadily become the focus of cancer research. It can increase tumor stem cell self-renewal and cell proliferation. The m6A-modified genes may be the primary focus for cancer breakthroughs. Although some endocrine cancers are rare, they may have a high mortality rate. As a result, it is critical to recognize the significance of endocrine cancers and identify new therapeutic targets that will aid in improving disease treatment and prognosis. We summarized the latest experimental progress in the m6A modification in endocrine cancers and proposed the m6A alteration as a potential diagnostic marker for endocrine malignancies.
format Online
Article
Text
id pubmed-9954123
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99541232023-02-25 The Emerging Role of m6A Modification in Endocrine Cancer Ji, Xiaoyu Wang, Zhiyuan Sun, Wei Zhang, Hao Cancers (Basel) Review SIMPLE SUMMARY: Endocrine tumors often cause hormonal imbalances and sometimes hormone syndrome. Generally, the prognosis of patients with metastatic endocrine malignancies is poor due to recurrence and treatment failure. Aberrant expression of m6A may disrupt the development and occurrence of malignancies. We provide a theoretical foundation for the development of new diagnostic markers and therapeutic techniques based on m6A alteration and regulators in endocrine cancers. ABSTRACT: With the development of RNA modification research, N6-methyladenosine (m6A) is regarded as one of the most important internal epigenetic modifications of eukaryotic mRNA. It is also regulated by methylase, demethylase, and protein preferentially recognizing the m6A modification. This dynamic and reversible post-transcriptional RNA alteration has steadily become the focus of cancer research. It can increase tumor stem cell self-renewal and cell proliferation. The m6A-modified genes may be the primary focus for cancer breakthroughs. Although some endocrine cancers are rare, they may have a high mortality rate. As a result, it is critical to recognize the significance of endocrine cancers and identify new therapeutic targets that will aid in improving disease treatment and prognosis. We summarized the latest experimental progress in the m6A modification in endocrine cancers and proposed the m6A alteration as a potential diagnostic marker for endocrine malignancies. MDPI 2023-02-06 /pmc/articles/PMC9954123/ /pubmed/36831377 http://dx.doi.org/10.3390/cancers15041033 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ji, Xiaoyu
Wang, Zhiyuan
Sun, Wei
Zhang, Hao
The Emerging Role of m6A Modification in Endocrine Cancer
title The Emerging Role of m6A Modification in Endocrine Cancer
title_full The Emerging Role of m6A Modification in Endocrine Cancer
title_fullStr The Emerging Role of m6A Modification in Endocrine Cancer
title_full_unstemmed The Emerging Role of m6A Modification in Endocrine Cancer
title_short The Emerging Role of m6A Modification in Endocrine Cancer
title_sort emerging role of m6a modification in endocrine cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954123/
https://www.ncbi.nlm.nih.gov/pubmed/36831377
http://dx.doi.org/10.3390/cancers15041033
work_keys_str_mv AT jixiaoyu theemergingroleofm6amodificationinendocrinecancer
AT wangzhiyuan theemergingroleofm6amodificationinendocrinecancer
AT sunwei theemergingroleofm6amodificationinendocrinecancer
AT zhanghao theemergingroleofm6amodificationinendocrinecancer
AT jixiaoyu emergingroleofm6amodificationinendocrinecancer
AT wangzhiyuan emergingroleofm6amodificationinendocrinecancer
AT sunwei emergingroleofm6amodificationinendocrinecancer
AT zhanghao emergingroleofm6amodificationinendocrinecancer